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Abstract 
Background: The aim of the present study was to evaluate the efficacy of autologous serum eye drop in 
treatment of recurrent corneal epithelial defect. 
Materials and Methods: Fourteen patients with recurrent corneal epithelial defect were studied. Autologous 
serum was prepared from the patients and diluted in 20% normal saline. The patients were instructed to use the 
autologous serum every six hours. Patients were followed for a mean period of 18 months. 
Results: Four males (28.6%) and 10 females (71.4%) entered the study. Four patients stopped the treatment 
after three months with complete satisfaction from treatment. Patients reported a reduction in frequency and 
severity of attacks 4.6±2 weeks after the start of treatment. The mean number of attacks before the procedure 
was 7.6±0.9 per year which was reduced to 2.2±0.9 per year after treatment (p<0.001). The main side effects 
in patients were eye pruritus and redness which were well tolerated by patients. 
Conclusion: Autologous serum application seems to be a safe and effective method to treat recurrent corneal 
epithelial defect. 
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Recurrent corneal epithelial defect is a relatively 
common disease often starting with an epithelial 
scratch or in a person with primary epithelial 
basement membrane dystrophy, and causes recurrent 
epithelial defects
1
. It causes pain, foreign body 
sensation and redness of the eyes
1
. The interval 
between the episodes of recurrent corneal epithelial 
defect might be a few days or a few years
2
. These 
attacks in most people are mild and occur with long 
intervals, so the patient does not see an 
ophthalmologist and the epithelial defect heals itself 
but some patients experience more frequent or more 
severe episodes which cause them to seek treatment. 
The usual treatments in acute phase are antibiotic 
drops, contact lens and hypertonic (%5) saline eye 
drop which might be used for months
2
. These 
treatments usually affect but a few patients still show 
recurrence despite above mentioned treatments. 
Autologous serum drops have been used to treat 
refractory corneal epithelial defect in various 
diseases
3-8
. Autologous serum contains vitamins A, 
epithelial growth factor, fibronectin and transforming 
growth factor- ß, which are all important factors in the 
proliferation and migration of corneal epithelial 
cells
3,4
. The present study was designed to investigate 
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the use of autologous serum in treatment of recurrent 
corneal epithelial defect in this group of patients. 
Methods 
In this prospective study 14 patients with recurrent 
corneal epithelial defect which was not responding to 
conventional treatments underwent treatment using 
autologous serum. Informed consent was provided by 
patient and the study was approved by ethic 
committee of Shahid Beheshti University of Medical 
Sciences. All patients had baseline corneal epithelial 
defects at the start of study and had at least three 
recurrence episodes in 6 months prior to entering the 
study. None of the patients had clear signs of corneal 
epithelial basement membrane dystrophy or other 
corneal dystrophies. We excluded patients with dry 
eye and any evidence of Meibomian gland 
dysfunction. 
From each patient 10cc of whole blood was taken 
and was kept at room temperature until clot 
formation was complete. Then it was centrifuged for 
ten minutes. Serum was taken and after filtering was 
diluted to %20 using normal saline. The resulting 
solution was poured in 5cc bottles and was stored at -
20 degrees centigrade. Freezed bottles were given to 
patients and patients were instructed to move one 
bottle to 4 degrees centigrade part of their 
refrigerator and wait for it to thaw before usage. 
Patients were instructed to use the drops every six 
hours for at least three months after all their 
symptoms were subsided. Patients also received 
Chloramphenicol eye drops every 6 hours and NaCl 
5% eye ointment every night. Autologous serum was 
prescribed one drop every 6 hours. Patients were 
examined daily until the epithelial defect improved. 
After the epithelial defect healed the 
Chloramphenicol eye drop was stopped but NaCl 5% 
eye ointment and autologous serum drop were 
continued for at least 3 months after healing. Patients 
were followed for an average of 18 months (12 to 24 
months) after the start of treatment. 
Results 
Fourteen patients with a mean age of 35±10.3 years 
(median: 32 years, range 58-25 years) were enrolled 
in this study. Four patients (28.6%) were male and 10 
patients (71.4%) were female. 
A history of corneal abrasion by an object or nail 
scratch was present in 11 patients (78.6%). 
Patients were treated for on average of 4 months with 
autologous serum. Patients were followed for an 
average of 18.7±4.7 months. Four patients 
discontinued the treatment after 3 months with near 
complete subside of their symptoms.  
In average after 2±4.6 weeks of treatment, patients 
reported a reduction of the severity and frequency of 
attacks. Complications during treatment were red and 
itchy eyes, in three patients (21.4%) and one patient 
(7.1%), respectively. Another three patients (21.4%) 
showed both symptoms. Severity of complications in 
patients with intolerance to treatment was not enough 
to create a group as intolerance to treatment. 
Discussion 
The classic treatment for recurrent corneal epithelial 
defect is helpful in most patients but a small 
percentage of patients are still suffering from the 
disease attacks despite prophylactic treatments. 
Uses of autologous serum drops in treatment of 
persistent defects of the corneal epithelium has been 
investigated in various studies
3-8
, but based on our 
knowledge use of autologous serum drops to treat 
recurrent epithelial defect has not been previously 
studied in Iran. Fourteen patients in our study had 
corneal epithelial defects but the epithelial defect was 
not stable. Patients were chosen to be treated with this 
method because of frequent and severe attacks and no 
response to treatment using usual methods.  
Serum contains a number of biological factors that can 
affect the healing process. For example, serum 
contains factors that stimulate epithelial mitosis such 
as: substance P
9,10
, extracellular matrix components 
such as; fibronectin, growth factors for the onset of 
epithelial cell migration (like; transforming growth 
factor ß, epithelial growth factor) and growth factors 
stimulating epithelial cells in mitosis (EGF); protease 
inhibitors and anti-apoptosis factors
11
. It is not fully 
known how each of these factors accelerate epithelial 
repair, but on the whole, these factors facilitate the 
healing of epithelial defects
12
. 
Studies have indicated the gelatinase (matrix 
metalloprotease 2 and 9 enzymes) activity in corneal 
epithelium of recurrent epithelial defect is higher than 
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average
13
. Gelatinase has a negative effect on the 
basal epithelial cell repair by breaking different types 
of collagen such as; X, VII, V and IV. 
Metalloproteinase family enzymes influence 
negatively on adhesion molecules (like fibronectin 
and Laminin) which create adhesion between cells in 
the basal layer of epithelium and basement 
membrane
13
. Totally, these factors weaken the 
binding of epithelial cells to the basement membrane. 
In our study, autologous serum usage reduced the 
incidence of recurrent attacks which was probably 
because of strengthening of connections between the 
epithelial cells and basement membrane.  
A complication during treatment was eye redness and 
itching which did not lead to treatment rejection by 
the patient. According to the results obtained from 
our study it might be possible to use autologous 
serum as a replacement therapy in patients with 
recurrent epithelial defect.  
The low number of samples and lack of a control 
group are some deficiencies of the present study and 
to reach more reliable results double blind controlled 
randomized trials are suggested.  
Conclusion 
Autologous serum application seems to be a safe and 
effective method to treat recurrent corneal epithelial 
defect. 
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